Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles

A new series of CB 1 receptor antagonists incorporating an imidazole-based isosteric replacement for the hydrazide moiety of rimonabant (SR141716) is disclosed. Members of this imidazole series possess potent/selective binding to the rCB 1 receptor and exhibit potent hCB 1 functional activity. Isopr...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 19; no. 18; pp. 5351 - 5354
Main Authors Dow, Robert L., Hadcock, John R., Scott, Dennis O., Schneider, Steven R., Paight, Ernest S., Iredale, Philip A., Carpino, Philip A., Griffith, David A., Hammond, Marlys, DaSilva-Jardine, Paul
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier Ltd 15.09.2009
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A new series of CB 1 receptor antagonists incorporating an imidazole-based isosteric replacement for the hydrazide moiety of rimonabant (SR141716) is disclosed. Members of this imidazole series possess potent/selective binding to the rCB 1 receptor and exhibit potent hCB 1 functional activity. Isopropyl analog 9a demonstrated activity in the tetrad assay and was orally-active in a food intake model.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2009.07.130